DCM
DSGN icon

Driehaus Capital Management’s Design Therapeutics DSGN Stock Holding History

Driehaus Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
1,744,987
+565,170
+48% +$5.72M 0.14% 212
2025
Q4 		$11.1M Buy
1,179,817
+103,581
+10% +$811K 0.08% 270
2025
Q3 		$8.1M Hold
1,076,236
– – 0.06% 294
2025
Q2 		$3.63M Buy
1,076,236
+162,837
+18% +$609K 0.03% 314
2025
Q1 		$3.53M Buy
913,399
+137,317
+18% +$655K 0.03% 310
2024
Q4 		$4.79M Buy
+776,082
New +$4.49M 0.04% 297

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Driehaus Capital Management's DSGN Position: Q1 2026 in Review

Driehaus Capital Management increased its Design Therapeutics (DSGN) stake by 48% in Q1 2026, buying an estimated $5.72M and bringing the position to 1,744,987 shares worth $18.6M. The position accounts for 0.14% of the portfolio, ranked #212.

Driehaus Capital Management first reported a position in DSGN in Q4 2024 and has held it in 6 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Driehaus Capital Management held 1,744,987 shares of Design Therapeutics worth $18.6M as of Q1 2026.
  • Driehaus Capital Management bought 565,170 Design Therapeutics shares in Q1 2026, an estimated $5.72M.
  • Design Therapeutics made up 0.14% of Driehaus Capital Management's portfolio in Q1 2026, its #212 holding.
  • Driehaus Capital Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.